Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics

Warning

This publication doesn't include Faculty of Medicine. It includes Faculty of Pharmacy. Official publication website can be found on muni.cz.

Authors	FENG XJ SUREDA A JAFARI S MEMARIANI Z TEWARI D ANNUNZIATA G BARREA L HASSAN STS ŠMEJKAL Karel MALANÍK Milan SYCHROVÁ Alice BARRECA D ZIBERNA L MAHOMOODALLY MF ZENGIN G XU SW NABAVI SM SHEN AZ
Year of publication	2019
Type	Article in Periodical
Magazine / Source	Theranostics
MU Faculty or unit	Faculty of Pharmacy
Citation
Doi	http://dx.doi.org/10.7150/thno.30787
Keywords	berberine; cardiovascular diseases; metabolic diseases; targets; therapeutics
Description	Cardiovascular and metabolic diseases (CVMD) are the leading causes of death worldwide, underscoring the urgent necessity to develop new pharmacotherapies. Berberine (BBR) is an eminent component of traditional Chinese and Ayurvedic medicine for more than 2000 years. Recently, BBR has attracted much interest for its pharmacological actions in treating and/or managing CVMD. Recent discoveries of basic, translational and clinical studies have identified many novel molecular targets of BBR (such as AMPK, SIRT1, LDLR, PCSK9, and PTP1B) and provided novel evidences supporting the promising therapeutic potential of BBR to combat CVMD. Thus, this review provides a timely overview of the pharmacological properties and therapeutic application of BBR in CVMD, and underlines recent pharmacological advances which validate BBR as a promising lead drug against CVMD.